Comparison of the effectiveness of venlafaxine in peri- and postmenopausal patients with major depressive disorder

This study examines the difference in the efficacy and tolerability of an antidepressant inhibiting the reuptake of norepinephrine and serotonin--IRNS--on climacteric patients diagnosed of major depressive disorder, comparing the therapeutic response between perimenopausal and postmenopausal patient...

Full description

Saved in:

Bibliographic Details
Published in:	Actas espanolas de psiquiatria Vol. 38; no. 6; p. 326
Main Authors:	Iglesias García, C, Ocio León, S, Ortigosa Digón, J C, Merino García, M J, Alonso Villa, M J, Fernández Palicio, L, Alonso Rionda, J L, García Fernández, F, Rodríguez Colubi, L, Toimil Iglesias, A
Format:	Journal Article
Language:	English
Published:	Spain 01-11-2010
Subjects:	Antidepressive Agents, Second-Generation - therapeutic use Cyclohexanols - therapeutic use Depressive Disorder, Major - drug therapy Female Humans Middle Aged Perimenopause Postmenopause Prospective Studies Venlafaxine Hydrochloride
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study examines the difference in the efficacy and tolerability of an antidepressant inhibiting the reuptake of norepinephrine and serotonin--IRNS--on climacteric patients diagnosed of major depressive disorder, comparing the therapeutic response between perimenopausal and postmenopausal patients. Observational, prospective, open-label, multicenter study 24 weeks study. The sample consisted of women between 45 and 55 years diagnosed of major depressive disorder. The study drug was venlafaxine extended release at doses according to the investigator's clinical criteria. The efficacy was assessed using repeated measures of the scales: Hamilton Depression Rating Scale and Blatt-Kupperman Menopausal Index. 36 depressed women were included in the study and 35 completed it. The patient's age range was 47 to 55 years old. Throughout the study, a significant clinical improvement in depressive and hormonal symptoms was seen. The comparison of the pattern of improvement, according to the menstrual status of the patients, showed no significant different between pre and postmenopausal patients. Perimenopausal women reported a higher rate of adverse events. The Venlafaxine was effective in treating depressive and hormonal symptoms regardless of the menstrual status of climacteric patients with a slightly worse tolerance in perimenopause.
ISSN:	1578-2735